ribavirin has been researched along with Viremia in 167 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (3.59) | 18.7374 |
| 1990's | 12 (7.19) | 18.2507 |
| 2000's | 92 (55.09) | 29.6817 |
| 2010's | 54 (32.34) | 24.3611 |
| 2020's | 3 (1.80) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, CY; Hosing, C; Torres, HA; Westin, J; Zhang, HC | 1 |
| Azevedo Silva, M; Eliseu, L; Leal, C; Ruge Gonçalves, A | 1 |
| Boden, K; Bruns, T; Franz, A; Guliyeva, S; Reuken, PA; Rose, M; Stallmach, A | 1 |
| Applegate, TL; Backmund, M; Bruggmann, P; Cloherty, G; Conway, B; Cunningham, EB; Cunningham, P; Dalgard, O; Dore, GJ; Foster, GR; Grebely, J; Hajarizadeh, B; Lamoury, FMJ; Marks, P; Martinez, D; Robaeys, G; Soker, A; Swan, T | 1 |
| Antón, MD; Ferrando, I; Latorre, P; Moreno Osset, E; Pascual, A; Polanco, A | 1 |
| Eshita, Y; Fukuda, C; Gendo, Y; Hidano, S; Kamiyama, N; Kobayashi, T; Matsubara, E; Miura, Y; Noguchi, K; Ozaki, T; Runtuwene, LR; Sachi, N; Soma, R; Sonoda, A; Tajima, S; Takasaki, T; Umekita, H; Watanabe, K | 1 |
| Akondy, RS; Cannon, D; Ellebedy, AH; Harmon, JR; Klena, JD; Kraft, CS; Lyon, MG; McElroy, AK; Mehta, AK; Nichol, ST; Ribner, BS; Sette, A; Sidney, J; Spiropoulou, CF; Varkey, JB | 1 |
| Al Khalloufi, K; Flocco, G; Kapila, N; Zervos, XB | 1 |
| Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CC; Lin, CY; Lin, SM; Sheen, IS; Teng, W | 1 |
| Derniame, S; Gaspar, HB; Gilmour, K; Hiwarkar, P; Ip, W; McNicol, AM; Qasim, W; Veys, P; Zhan, H | 1 |
| Jia, Z; Li, D; Liang, HJ; Ma, L; Wei, X; Yang, D | 1 |
| Aguilera, V; Berenguer, M; Vinaixa, C | 1 |
| Barnard, RJ; Cheney, CA; Dinubile, MJ; Graham, DJ; Hazuda, DJ; Himmelberger, AL; Hwang, PM; McHale, CM; Mobashery, N; Newhard, W; Nickle, D; Reeves, JD; Rivera, AA; Strizki, J | 1 |
| Andonov, A; Lu, Y; Wong, DK | 1 |
| Aslam, S; Bremer, B; Cobb, B; Cornberg, M; Halfon, P; Luk, K; Maasoumy, B; Manns, MP; Wedemeyer, H | 1 |
| Alonso, S; Bárcena, R; Calleja, JL; Casanovas, T; Fernández-Rodríguez, CM; González, JM; Jorquera, F; Martín-Martín, L; Masnou, H; Miquel-Planas, M; Morillas, RM; Navarro, JM; Planas, R; Poyato, A; Romero-Gomez, M; Salmerón, J; Solà, R | 1 |
| Aghemo, A; Colombo, M; Falconer, K; Lunghi, G; Sarrazin, C; Susser, S; Vermehren, J; Weiland, O; Zeuzem, S | 1 |
| Ahmed, AI; Aziz, IA; Bahnasy, KA; Fathelbab, IF; Hafez, TA; Kamal, SM; Kassim, SK; Mahmoud, S; Mansour, HM | 1 |
| Barrero Alor, F; Casado Monge, PG; Jiménez Macías, FM; Pujol de la Llave, E; Ramos Lora, M; Ruíz-Frutos, C | 1 |
| Cetin, I; Gülhan, B; Ozkaya Parlakay, A; Tezer, H | 1 |
| Allen, TM; Park, SH; Rehermann, B; Tully, DC; Veerapu, NS | 1 |
| Haagmans, BL; Koopmans, MP; Koulouris, NG; Koutsoukou, A; Osterhaus, AD; Pontikis, K; Raj, VS; Spanakis, N; Tsakris, A; Tsiodras, S | 1 |
| Chang, CS; Cho, SF; Chuang, WL; Hsiao, HH; Hsiao, SY; Hsu, JF; Lin, SF; Liu, TC; Liu, YC; Tsai, HJ; Wang, HC; Wu, CH; Yu, ML | 1 |
| Arastéh, K; Bhagani, S; Dieterich, D; Guardiola, JM; Ingiliz, P; Jain, MK; Kort, J; Laguno, M; Manero, M; Nelson, M; Rockstroh, JK; Soriano, V; Stern, JO; Tural, C; Vinisko, R | 1 |
| Albandea Moreno, C; Bautista Galán, C; Ruiz Arredondo, J; Serrato, AR | 1 |
| Bárcena, R; Berenguer, M; Buti, M; Calleja, JL; Crespo, J; Fernández, I; González, O; López, J; Pérez, F | 1 |
| Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A | 1 |
| Gonzalez-Peralta, RP; Jonas, MM; Lobritto, SJ; Mogul, D; Molleston, JP; Murray, KF; Pavlovic, V; Rosenthal, P; Schwarz, KB; Thompson, B; Warne, C; Wat, C; Wen, J | 1 |
| Antonov, K; Boyanova, Y; Caloska-Ivanova, V; Dimovski, A; Dumitrascu, D; Dzekova-Vidimliski, P; Joksimovic, N; Mateva, L; Matevska-Geshkovska, N; Nikolov, IG; Nikolova, N; Romanciuc, G; Rostaing, L; Sikole, A | 1 |
| Khatun, A; Kim, BS; Kim, WI; Seo, BJ; Shabir, N; Yoon, KJ | 1 |
| Boglione, L; Cusato, J; D'Avolio, A; Di Perri, G | 1 |
| Darwish, T; Ghoneum, M; Medhat, E; Salama, H; Shaheen, M; Zekri, AN | 1 |
| Hmwe, SS; Ide, T; Inoue, T; Kato, K; Kumada, T; Shimada, N; Takaguchi, K; Tanaka, Y; Torimura, T; Toyoda, H; Tsubota, A; Wakita, T | 1 |
| Chang, WY; Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yang, YH; Yu, ML | 1 |
| Gasztonyi, B; Lombay, B; Szalay, F | 1 |
| Husa, P; Husová, L; Slesinger, P; Stroblová, H; Svobodník, A | 1 |
| Agostinacchio, E; Andriulli, A; Bacca, D; Carretta, V; Cozzolongo, R; Mangia, A; Minerva, N; Petruzzellis, D; Ricci, GL; Romano, M; Scotto, G; Sogari, F; Vinelli, F | 1 |
| Diago, M | 1 |
| Chokshi, S; Cooksley, H; Farmakiotis, D; Michalak, TI; Naoumov, NV; Pachiadakis, I; Sarrazin, C; Zeuzem, S | 1 |
| Jeong, S; Kim, CH; Kim, HG; Kim, YS; Kwon, KS; Lee, DH; Lee, JI; Lee, JW; Park, BD; Shin, YW | 1 |
| Bortolotti, F | 1 |
| Asjø, B; Myrmel, H; Ulvestad, E | 1 |
| Brodanová, M; Brůha, R; Dusek, L; Janousová, E; Marecek, Z; Petrtýl, J; Subhanová, I; Urbánek, P | 1 |
| Coppola, N; Iodice, V; Macera, M; Piccinino, F; Sagnelli, E; Stanzione, M; Tonsiello, G | 1 |
| Birch, CE; Bowen, MJ; Chung, RT; Kim, AY; McGovern, BH; Nagami, EH; Reyor, LL | 1 |
| Alonso López, S; Fernández Rodríguez, CM | 1 |
| Cabanillas, M; de la Santa, E; Domper, F; Galván, MD; Hernández, A; León, A; López, B; Lorente, R; Olmedo, J; Patón, R; Rodríguez, E | 1 |
| Afendy, A; Baranova, A; Birerdinc, A; Manyam, G; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| Duffin, RP; Ichim, TE; Joyce, JA; Levin, NW; Tullis, RH | 1 |
| Colucci, G; Hadziyannis, SJ; Ishida, H; Lin, A; Sarrazin, C; Shiffman, ML; Zeuzem, S | 1 |
| Arnholm, B; Buhl, MR; Eilard, A; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Mørch, K; Nilsson, S; Norkrans, G; Pedersen, C; Wahlberg, T; Wejstål, R; Westin, J | 1 |
| Engström, L; Lewensohn-Fuchs, I; Ljungman, P; Omar, H; Orvell, C; Pérez-Bercoff, L; Vuong, GK; Yun, Z | 1 |
| El Diasty, A; Saudy, N; Zaki, Mel S | 1 |
| Jung, EU; Kang, HG; Lee, SH; Lee, YJ; Moon, SS; Park, SJ; Seo, JA; Seol, SY | 1 |
| Beste, LA; Chapko, M; Dominitz, JA; Ioannou, GN; Larson, MS | 1 |
| Alonzi, D; Block, TM; Borune, N; Butters, TD; Chang, J; Goh, A; Guo, JT; Kinch, MA; Lakshminarayana, SB; Liu, B; Moriarty, R; Pan, X; Qu, X; Rayahin, JE; Reinkensmeier, G; Schul, W; Shi, PY; Wang, L; Weidner, JM; Xu, X; Yip, A; Yu, W | 1 |
| Alberti, A; Bortoletto, G; Campagnolo, D; Comastri, G; Mirandola, S; Pulvirenti, FR; Severini, L | 1 |
| Blanco, JL; Calvo, M; González, A; Laguno, M; Larrousse, M; Loncà, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Muñoz, A | 1 |
| Baleriola, C; Chaverot, S; Cheng, W; Crawford, D; Dore, GJ; Dubois, D; McCaughan, G; Rawlinson, WD; Rizkalla, B; Roberts, S; Sievert, W; Stelzer-Braid, S; Thommes, J; Weltman, M; Yoshihara, M | 1 |
| Bozzano, F; Costa, P; De Maria, A; Fazio, V; Hirsch, I; Marras, F; Moretta, L; Olive, D; Picciotto, A | 1 |
| Alcaide, N; Aller, R; Almansa, R; Bermejo-Martín, JF; Caro-Patón, A; de la Fuente, C; González, JM; Jiménez-Sousa, MÁ; Largo, P; Ortiz de Lejarazu, R; Ruiz, L; Sánchez-Antolín, G | 1 |
| El-Serag, HB; Kanwal, F; Kramer, JR; Mei, M; Richardson, P | 1 |
| Berg, T; Böhm, S; Buggisch, P; Gerlach, T; Hinrichsen, H; Klinker, H; Möller, B; Neumann, K; Rasenack, J; Sarrazin, C; Spengler, U; Teuber, G; Weich, V; Wiegand, J | 1 |
| Aoyagi, Y; Enjoji, M; Fujino, T; Fukuda, M; Ishibashi, H; Kohjima, M; Nakamuta, M; Satoh, T; Yatsuhashi, H | 1 |
| Dorantes, B; Eslam, M; Gallego-Durán, R; García-Collado, C; Grande, L; Morillo, R; Paradas, C; Pardo-Yules, B; Romero-Gómez, M | 1 |
| Abdel-Mohsen, M; Battegay, M; Bernasconi, E; Fellay, J; Fujimoto, K; Greene, WC; Guatelli, J; Günthard, HF; Hirschel, B; Kovari, H; Ledergerber, B; Monto, A; Pillai, SK; Rauch, A; Skasko, M; Witteck, A; Wong, JK; Yukl, S | 1 |
| Adamek, A; Bereszyńska, I; Bura, A; Bura, M; Czajka, A; Hryckiewicz, K; Kowala-Piaskowska, A; Mozer-Lisewska, I | 1 |
| Berg, T; Biermer, M; Brodzinski, A; Fülöp, B; Heyne, R; Keller, K; Sarrazin, C; Schlosser, B; van Bömmel, F | 1 |
| Aichelburg, MC; Breitenecker, F; Ferlitsch, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Schmied, B; Sieghart, W; Trauner, M | 1 |
| Abdallah, el S; Ahmed, R; Ahmed, Sel-D; Darwish, T; Omar, D; Sabry, D; Salama, H | 1 |
| Hilleret, MN; Leroy, V | 1 |
| Almasio, P; Cappello, M; Cino, N; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Vaccaro, A | 1 |
| Durández Lazaro, R; Fábregas Puigtió, S; Planas Vilà, R; Vega Palomares, R | 1 |
| Dorak, MT; Folayan, GO; Kaslow, RA; Niwas, S; Tang, J; van Leeuwen, DJ; Yee, LJ | 1 |
| Cacoub, P; Duhaut, P; Ghillani, P; Leger, JM; Lidove, O; Maisonobe, T; Myers, RP; Piette, JC; Servan, J; Thibault, V | 1 |
| Chen, DS; Chen, PJ; Jeng, YM; Kao, JH; Lai, MY; Liu, CJ | 1 |
| Castedal, M; Friman, S; Olausson, M; Siewert-Delle, A | 1 |
| Gopal, DV; Rosen, HR | 1 |
| Abergel, A; Alleman, I; Arpurt, JP; Bailly, F; Bernard, PH; Blanc, F; Botta-Fridlund, D; Botti, G; Bourlière, M; Caroli-Bosc, F; Chazouillères, O; Couzigou, P; De Lédinghen, V; Debonne, JM; Doll, F; Ducloux, S; Eugène, C; Gauthier, AP; Gérolami, A; Gérolami, V; Gouvernet, J; Grimaud, JC; Halfon, P; Khiri, H; Larrey, D; Mathieu-Chandelier, C; Moreau, X; Ouzan, D; Picon, M; Pol, S; Portal, I; Sogni, P; Thiefin, G; Vetter, D; Zamora, C | 1 |
| Cointault, O; Durand, D; Izopet, J; Kamar, N; Ribes, D; Rostaing, L; Sandres-Saune, K; Selves, J | 1 |
| Guntz, P; Lunel, F; Maniez-Montreuil, M; Payan, C; Picchio, G; Veillon, P | 1 |
| Berkowitz, D; Hartman, C; Rimon, N; Shamir, R | 1 |
| Allison, M; Carithers, RL; Elizaga, M; Gaba, K; Gretch, DR; McElrath, MJ; Morishima, C; Musey, L | 1 |
| Wilde, JT | 1 |
| Lobos, IV; Marinho, RT; Moura, MC; Pinto, R; Santos, ML | 1 |
| Bailey, KW; Beadle, JR; Hostetler, KY; Sidwell, RW; Smee, DF; Wong, MH | 1 |
| García-Samaniego, J; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Berthillon, P; Buti, M; Esteban, JI; Manns, MP; Marcellin, P; Martinot, M; Maynard, M; Picchio, G; Pradat, P; Tillmann, HL; Trepo, C; Voirin, N; Wiegand, J | 1 |
| Asahina, Y; Hamano, K; Inoue, K; Itakura, J; Izumi, N; Kurosaki, M; Miyake, S; Nishimura, Y; Tsuchiya, K; Uchihara, M; Ueda, K | 1 |
| Buti, M | 1 |
| Alarcón, C; Arambarri, M; Echarri, R; Fernández Lucas, M; Merino, JL; Ortuño, J; Teruel, JL | 1 |
| Bain, C; Dubois, V; Duverger, B; Gebuhrer, L; Inchauspé, G; Komurian-Pradel, F; Lavergne, JP; Paranhos-Baccala, G; Parroche, P; Penin, F; Trépo, C; Vieux, C | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Lee, LP; Lin, ZY; Wang, LY; Yu, ML | 1 |
| Bonder, A; Fuentes, AP; Gallegos-Orozco, JF; García-Sandoval, M; Gutiérrez-Reyes, G; Gutiérrez-Ruíz, MC; Kershenobich, D; Loaeza-del Castillo, A; Olivera, MA; Rodríguez, R; Soto, L | 1 |
| Andrade, RJ; Castillo, J; Corpas, R; Cruz, M; Del Mar Viloria, M; Diago, M; Fernández-Rodríguez, CM; Gila, A; Grande, L; Gutiérrez, ML; López-Serrano, P; Muñoz-De-Rueda, P; Pérez, C; Romero-Gómez, M; Ruiz-Extremera, A; Salmerón, J; Suárez, E; Vázquez, L | 1 |
| Antonaci, A; Antonaci, S; Giannelli, G; Maddalena, G; Napoli, N; Parisi, CV | 1 |
| Barnes, DS; Bringman, D; Carey, WD; Farmer, D; Ferguson, R; Gramlich, T; Levinthal, G; Martin, LM; McCullough, AC; Mullen, KD; O'Shea, R; Ong, JP; Post, A; Tavill, AS; Younossi, ZM | 1 |
| Enomoto, M; Habu, D; Kawada, N; Kohmoto, M; Nishiguchi, S; Sakaguchi, H; Seki, S; Shiomi, S; Takeda, T; Tamori, A | 1 |
| Bárcena, R; Blesa, C; Fortún, J; García, M; García-Garzón, S; Martín-Dávila, P; Mateos, ML; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Otón, E; Quereda, C | 1 |
| Anderson, F; Friesenhahn, M; Gish, R; Gordon, S; Holodniy, M; Krajden, M; McHutchison, J; Pawlotsky, JM; Perrillo, R; Terrault, NA; Zitron, I | 1 |
| Bläckberg, J; Carlsson, T; Norkrans, G; Reichard, O; Sangfelt, P; Wallmark, E; Weiland, O | 1 |
| Diago, M; Giménez, MD; González, V; Matas, L; Montoliu, S; Morillas, RM; Padilla, E; Pérez, C; Planas, R; Solà, R | 1 |
| Chokshi, S; Cooksley, H; Herrmann, E; Naoumov, NV; Tang, KH; Tatman, N; Williams, R; Zeuzem, S | 1 |
| Changchien, CS; Chen, CL; Chen, WJ; Huang, WS; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Lai, CL; Yuen, MF | 1 |
| Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W | 1 |
| Alberti, A; Bortoletto, G; Dal Pero, F; Fagiuoli, S; Ferrari, A; Gerotto, M; Pistis, R; Realdon, S; Sebastiani, G | 1 |
| Albrecht, J; Brass, C; Buti, M; Cianciara, J; Ferenci, P; Horsmans, Y; Ibranyi, E; Noviello, S; Sperl, J; Weiland, O; Zeuzem, S | 1 |
| Navarro, JM; Sánchez-Seco, MP | 1 |
| Butensky, E; Foote, D; Harmatz, P; Pakbaz, Z; Vichinsky, EP; Walters, MC | 1 |
| Aghemo, A; D'Ambrosio, R; Rumi, MG | 1 |
| Alshuth, U; Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Heintges, T; Kallinowski, B; Klinker, H; Martus, P; Nasser, S; Pape, GR; Rasenack, J; Sarrazin, C; Schmidt, WE; Spengler, U; von Wagner, M; Zeuzem, S | 1 |
| Husa, P; Slesinger, P; Stroblová, H; Svobodník, A | 1 |
| Adachi, Y; Fujita, N; Horiike, S; Iwasa, M; Kai, M; Kaito, M; Konishi, M; Sugimoto, R; Tanaka, H; Watanabe, S | 1 |
| Bärthel, E; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 1 |
| Burioni, R; Carletti, S; Clementi, M; Craxì, A; Craxì, RD; Mancini, N; Perotti, M; Romanò, L; Zanetti, AR | 1 |
| Borovicka, J; Cerny, A; Dinges, S; Esteban, A; Gonvers, JJ; Helbling, B; Jochum, W; Knöpfli, M; Meyer-Wyss, B; Müllhaupt, B; Renner, EL; Stamenic, I; Wilhelmi, M | 1 |
| Bolkhir, A; Brunt, EM; Hayashi, PH; Solomon, HS | 1 |
| Flamand, M; Liu, W; Schul, W; Vasudevan, SG; Xu, HY | 1 |
| Ahmed, F; Gonzalez, SA; Jacobson, IM; Kadam, JS; Menezes, A | 1 |
| El-Shamy, A; Hotta, H; Imoto, S; Kim, SR; Nagano-Fujii, M; Sasase, N; Sasayama, M | 1 |
| Alestig, E; Arnholm, B; Eilard, A; Hellstrand, K; Lagging, M; Lindh, M; Norkrans, G; Wahlberg, T; Wejstål, R; Westin, J | 1 |
| Fytili, P; Manns, MP; Schaffer, S; Schulz, S; Tiemann, C; Wang, C; Wedemeyer, H | 1 |
| Berak, H; Horban, A; Kołakowska-Rzadzka, A; Krzysztof, B; Stańczak, JJ; Walewska-Zielecka, B; Wasilewski, M | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Adachi, Y; Fujita, N; Hamano, H; Ikoma, J; Imoto, I; Iwasa, M; Kaito, M; Kobayashi, Y; Kojima, Y; Yamauchi, K | 1 |
| De Angelis, D; Grieve, R; Irving, WL; Kwong, G; Ratib, S; Ryder, SD; Sweeting, M; Thomson, BJ | 1 |
| Bergin, C; Codd, M; Farrell, G; Mulcahy, F; Norris, S; Shea, DO; Tuite, H | 1 |
| Herrmann, E; Naoumov, NV; Pachiadakis, I; Paulon, E; Tang, KH; Tatman, N; Zeuzem, S | 1 |
| Cogliano-Shutta, NA; Connors, M; Davey, RT; Hallahan, CW; Johnson, AJ; Kottilil, S; Lempicki, RA; Lifson, JD; Luskin, MR; Manion, MM; Metcalf, JA; Mican, JM; Patamawenu, AA; Tilton, JC | 1 |
| Antonaci, A; Antonaci, S; Giannelli, G; Napoli, N | 1 |
| Cruciani, M; Franchini, M; Lippi, G; Mazzi, R; Mengoli, C; Veneri, D | 1 |
| Arakawa, T; Atsumi, H; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Nakano, S; Sone, Y; Tanikawa, M; Toyoda, H | 1 |
| Alaeus, A; Falconer, K; Gonzalez, VD; Michaëlsson, J; Moll, M; Reichard, O; Sandberg, JK | 1 |
| Jahrling, PB; Peters, CJ; Stephen, EL | 1 |
| Bassiakos, Y; Booth, D; Clax, PA; Connor, JD; Cooney, E; Crumpacker, CS; Erice, A; Griffith, BP; Holden-Wiltse, J; Hussey, S; Japour, AJ; Johanneson, N; Lertora, JJ; McLaren, C; Meehan, PM; Pollard, R; Timpone, J; Walesky, M; Wood, K | 1 |
| Collins, ML; Davis, GL; Detmer, J; Kolberg, JA; Lau, JY; Mizokami, M; Orito, E; Qian, K; Urdea, MS | 1 |
| Azoulay, D; Charpentier, B; Debuire, B; Ducret, F; Féray, C; Gigou, M; Lemoine, A; Paradis, V; Pham, HP; Samuel, D | 1 |
| Chen, DS; Chen, PJ; Chen, W; Kao, JH; Lai, MY | 1 |
| Bell, H; Bjøro, K; Gutigard, BG; Harthug, S; Hellum, K; Maeland, A; Myrvang, B; Raknerud, N; Ritland, S; Simmonds, P; Skaug, K; von der Lippe, B | 1 |
| Albrecht, J; Conrad, A; Elliot, M; Gianelli, G; Glue, P; McHutchison, J; Nyberg, L; Zambas, D | 1 |
| Abergel, A; Berthelot, P; Bourlière, M; Bréchot, C; Combis, JM; Couzigou, P; Larrey, D; Moussalli, J; Pol, S; Poupon, R; Tran, A | 1 |
| Civeira, MP; Prieto, J | 1 |
| Gretch, DR; Pawlotsky, JM | 1 |
| Castro, FJ; Dragon, EA; Esteban, JI; Esteban, R; Guardia, J; Sauleda, S; Viladomiu, L | 1 |
| Berg, T; Hopf, U; Kaul, T; Naumann, U; Wiedenmann, B | 1 |
| Baumgarten, R; Berg, T; Hoffmann, RM; Hopf, U; Lafrenz, M; Leifeld, L; Pape, GR; Spengler, U; Teuber, G; Zeuzem, S | 1 |
| Lagging, LM; Lindh, M; Nenonen, N; Norkrans, G; Wejstål, R; Westin, J | 1 |
| Andreoni, M; Biglino, A; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Colletta, C; Croce, G; Di Napoli, A; Macor, A; Maggi, G; Olivero, A; Orsi, PG; Rinaldi, E; Rizzetto, M; Roffi, L; Saracco, G; Smedile, A; Tappero, GF; Terreni, N | 1 |
| Zeuzem, S | 1 |
| Bain, VG | 1 |
| Pol, S | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Lai, MY | 1 |
| Beersma, MF; Drosten, C; Emmerich, P; Fleischer, K; Geisen, HP; Günther, S; Hoerauf, A; Köhler, B; Laue, T; Schmitz, H; Veldkamp, PJ | 1 |
| García-Samaniego, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Romero, M; Soriano, V | 1 |
| Barange, K; Hrycewycz, N; Izopet, J; Pascal, JP; Payen, JL; Sandres, K | 1 |
| Cooper, DA; Dore, GJ | 1 |
| Ray, SC; Sulkowski, MS; Thomas, DL | 1 |
| Grube, T; Hommann, M; Kornberg, A; Scheele, J; Schotte, U; Tannapfel, A; Voigt, R; Wagner, T | 1 |
| Gill, SK; Gilson, RJ; Loveday, C; Semple, M; Tedder, RS; Weller, IV | 1 |
| Cosgriff, TM; Hu, ZJ; Huggins, JW; Qu, CF; Smith, JI; Xiang, JM; Yang, ZQ; Zhang, MV; Zhang, TM; Zheng, ZM | 1 |
| Dalrymple, JM; Hasty, SE; Malinoski, FJ; Ussery, MA | 1 |
| Briggiler, AM; Canonico, PG; Enria, DA; Levis, S; Maiztegui, JI; Vallejos, D | 1 |
| Yang, ZQ | 1 |
| Avila, MM; Calello, MA; McCormick, JB; Merani, MS; Rodriguez, M; Weissenbacher, MC | 1 |
| Monath, TP | 1 |
| Belmont-Williams, R; Craven, RB; Elliott, LH; Johnson, KM; King, IJ; McCormick, JB; Scribner, CL; Webb, PA | 1 |
22 review(s) available for ribavirin and Viremia
| Article | Year |
|---|---|
The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Oligopeptides; Polyethylene Glycols; Publication Bias; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Risk; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load; Viremia | 2013 |
[Progress in hepatitis C treatment].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2013 |
[Clinical aspects of hepatitis C in women of child-bearing age].
Topics: Adolescent; Adult; Antiviral Agents; Contraindications; Female; Hepatitis C; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pregnancy; Pregnancy Complications, Infectious; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Viremia | 2008 |
[Treatment of hepatitis C virus infection: current status and perspectives].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load; Viremia | 2008 |
[Chronic hepatitis C in children: natural history and prognosis].
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Incidence; Interferons; Italy; Prevalence; Prognosis; Ribavirin; Risk Factors; Treatment Outcome; Viremia | 2009 |
The hepatitis C virus enigma.
Topics: Antigens, CD; Antiviral Agents; Biological Evolution; Disease Progression; Drug Synergism; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Receptors, Virus; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Tetraspanin 28; Viral Hepatitis Vaccines; Viremia; Virus Replication | 2009 |
[Treatment optimization in chronic hepatitis C virus infection].
Topics: Adult; Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Viremia | 2010 |
Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis.
Topics: Antiviral Agents; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Mannose-Binding Lectins; Models, Biological; Plant Lectins; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Sorption Detoxification; Treatment Outcome; Viral Load; Viremia | 2010 |
[Current status of acute hepatitis C].
Topics: Acute Disease; Antiviral Agents; Asymptomatic Diseases; Comorbidity; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin; Risk Factors; RNA, Viral; Sexual Behavior; Spain; Substance Abuse, Intravenous; Viremia | 2011 |
[Evaluation of response to treatment in chronic hepatitis C].
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Liver Neoplasms; Meta-Analysis as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Transaminases; Viremia | 2002 |
[Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
Topics: Acute Disease; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Depression; Drug Evaluation; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Hyperbilirubinemia; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Spain; Thyroiditis; Viral Load; Viremia | 2002 |
HIV and HCV coinfection in haemophilia.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Ribavirin; Transaminases; Viremia | 2004 |
[Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
Topics: Acute Disease; Antiviral Agents; Forecasting; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Remission, Spontaneous; Ribavirin; RNA, Viral; Viral Load; Viremia | 2004 |
Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.
Topics: Age Factors; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Multivariate Analysis; Mutation; Ribavirin; RNA, Viral; Species Specificity; Taiwan; Treatment Outcome; Viral Nonstructural Proteins; Viremia | 2006 |
[Infections due to Toscana virus, West Nile virus, and other arboviruses of interest in Europe].
Topics: Africa, Northern; Animals; Antiviral Agents; Arbovirus Infections; Arboviruses; Birds; Europe; Female; Humans; Insect Vectors; Israel; Male; Mammals; Phlebotomus Fever; Population Surveillance; Ribavirin; Russia; Sandfly fever Naples virus; Viremia; West Nile Fever | 2005 |
Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome; Viremia | 2008 |
Early predictors of response to treatment in patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Viremia | 1999 |
Molecular tools for the treatment of hepatitis C.
Topics: Antiviral Agents; Biomarkers; Drug Resistance, Microbial; Genetic Techniques; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Time Factors; Viral Load; Viremia; Virus Replication | 1998 |
The kinetics of hepatitis C virus infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Kinetics; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia; Virus Replication | 2001 |
Effect of HCV viral dynamics on treatment design: lessons learned from HIV.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Viremia | 2001 |
[HVB and HVC infections in nephrology].
Topics: Antiviral Agents; Comorbidity; Contraindications; Graft Rejection; Hepatitis B; Hepatitis C; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Lamivudine; Liver Cirrhosis; Postoperative Complications; Renal Dialysis; Ribavirin; Vaccination; Viral Hepatitis Vaccines; Viremia | 2001 |
The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.
Topics: Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Hepatitis B; Hepatitis C; HIV Infections; Humans; Lamivudine; Liver; Ribavirin; Viremia | 2001 |
37 trial(s) available for ribavirin and Viremia
| Article | Year |
|---|---|
Interferon-γ capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Adolescent; Antigens, Viral; Antiviral Agents; Capsid Proteins; Child; Chromatography, Liquid; Cidofovir; Combined Modality Therapy; Cytosine; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunomagnetic Separation; Immunosuppressive Agents; Immunotherapy, Adoptive; Infant; Infant, Newborn; Interferon gamma Receptor; Interferon-gamma; Lymphocyte Transfusion; Organophosphonates; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Interferon; Ribavirin; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Transplantation, Homologous; Viremia | 2013 |
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Peptide Hydrolases; Polyethylene Glycols; Proline; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viremia; Young Adult | 2013 |
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2014 |
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Leucine; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load; Viremia; Young Adult | 2015 |
Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Oryza; Ribavirin; Viral Load; Viremia; Xylans | 2016 |
Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
Topics: Aged; Antiviral Agents; Cell Line; Drug Synergism; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Transfection; Treatment Outcome; Viral Load; Viremia | 2017 |
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 2008 |
Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection.
Topics: Acute Disease; Adult; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia; Young Adult | 2009 |
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia; Young Adult | 2011 |
Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Salvage Therapy; Thalidomide; Treatment Outcome; Viral Load; Viremia | 2011 |
Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2002 |
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2003 |
Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Function Tests; Kidney Transplantation; Liver; Liver Function Tests; Male; Middle Aged; Necrosis; Pilot Projects; Proteinuria; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2003 |
A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2004 |
Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2005 |
Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Outcome and Process Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia | 2005 |
Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia | 2005 |
Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
Topics: Antiviral Agents; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C; Hong Kong; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Species Specificity; Treatment Outcome; Viremia | 2006 |
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2006 |
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2006 |
Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperlipidemias; Hypolipidemic Agents; Interferons; Male; Middle Aged; Pilot Projects; Prospective Studies; Ribavirin; RNA, Viral; Viremia | 2006 |
Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Topics: 5' Untranslated Regions; Adult; Antibody Specificity; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Epitopes; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Male; Middle Aged; Molecular Conformation; Neutralization Tests; Polyethylene Glycols; Ribavirin; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Envelope Proteins; Viremia | 2006 |
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.
Topics: Adult; Aged; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viremia | 2006 |
Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin.
Topics: Adult; Antibodies; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lactoferrin; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2007 |
Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics as Topic; Viremia | 2008 |
The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2008 |
Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Viremia | 2009 |
A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; Genetic Variation; Giant Cells; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Viremia | 1996 |
Effect of interferon-alpha and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV-C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Chronic Disease; DNA, Viral; Drug Therapy, Combination; Female; Flaviviridae; Genetic Techniques; Hepatitis C; Hepatitis, Viral, Human; Humans; Interferon Type I; Liver; Male; Middle Aged; Molecular Sequence Data; Phylogeny; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, DNA; Viremia | 1997 |
Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Topics: Adult; Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 1999 |
Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 1999 |
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Topics: Antiviral Agents; Combined Modality Therapy; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viremia | 1999 |
[Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Topics: Adult; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2000 |
Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2000 |
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2001 |
Interruption study of viremia of patients with hemorrhagic fever with renal syndrome in the febrile phase.
Topics: Double-Blind Method; Fever; Hemorrhagic Fever with Renal Syndrome; Humans; Ribavirin; Viremia | 1991 |
[Interruption of early viremia in patients with epidemic hemorrhagic fever].
Topics: Double-Blind Method; Female; Hemorrhagic Fever with Renal Syndrome; Humans; Immunoglobulin M; Male; Orthohantavirus; Ribavirin; Ribonucleosides; Viremia | 1989 |
108 other study(ies) available for ribavirin and Viremia
| Article | Year |
|---|---|
Hepatitis E Virus Infection in Cancer Patients.
Topics: Adult; Female; Hematologic Neoplasms; Hepatitis E; Hepatitis E virus; Humans; Male; Neoplasms; Retrospective Studies; Ribavirin; RNA; United States; Viremia | 2022 |
Severe hepatitis E in an immunocompetent young female treated with ribavirin.
Topics: Adult; Female; Hepatitis E; Hepatitis E virus; Humans; Ribavirin; Viremia; Young Adult | 2023 |
Early ribavirin for hepatitis E virus infection in patients receiving immunosuppressive therapy: a retrospective, observational study.
Topics: Hepatitis E virus; Humans; Immunosuppression Therapy; Retrospective Studies; Ribavirin; Viremia | 2023 |
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
Topics: Adult; Antiviral Agents; Drug Users; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Immunoassay; Male; Middle Aged; Molecular Diagnostic Techniques; Recurrence; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sustained Virologic Response; Treatment Outcome; Viral Core Proteins; Viral Load; Viremia | 2017 |
Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals.
Topics: Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Viremia; Virus Activation | 2018 |
Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; DNA Replication; Mice; Ribavirin; STAT1 Transcription Factor; Vero Cells; Viremia; Virus Replication; Zika Virus; Zika Virus Infection | 2017 |
A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.
Topics: Adult; Amides; Antibodies, Viral; Antigens, Viral; Antiviral Agents; CD8-Positive T-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Humans; Immunity, Cellular; Immunoglobulin Class Switching; Lassa Fever; Lassa virus; Lymphocyte Activation; Male; Pyrazines; Ribavirin; Viremia | 2017 |
Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; Tissue Donors; Transplant Recipients; Viremia | 2019 |
Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Proportional Hazards Models; Retrospective Studies; Ribavirin; Secondary Prevention; Sustained Virologic Response; Taiwan; Tertiary Prevention; Viral Load; Viremia | 2019 |
Hepatitis C virus late relapse after sustained virologic response from interferon and ribavirin treatment as confirmed by RNA sequencing.
Topics: Cluster Analysis; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Middle Aged; Phylogeny; Recurrence; Ribavirin; RNA, Viral; Sequence Analysis, RNA; Sequence Homology; Viral Envelope Proteins; Viremia | 2014 |
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viremia | 2014 |
Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Viral Load; Viremia | 2014 |
Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
Topics: Acute Disease; Adult; Age Distribution; Antiviral Agents; Case-Control Studies; Confidence Intervals; Disease Progression; Egypt; Female; GB virus C; Genotype; Hepacivirus; Hepatitis C; Humans; Incidence; Interferons; Interleukins; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribavirin; RNA, Viral; Sex Distribution; Statistics, Nonparametric; Treatment Outcome; Viral Load; Viremia | 2014 |
[Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cholesterol; Drug Therapy, Combination; False Positive Reactions; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Hypertriglyceridemia; Interferon-alpha; Interferons; Interleukins; Lipids; Lipoproteins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Load; Viremia | 2015 |
Bradycardia related to ribavirin in four pediatric patients with Crimean-Congo hemorrhagic fever.
Topics: Adolescent; Animals; Antiviral Agents; Arachnid Vectors; Bradycardia; Child; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; Humans; Ribavirin; Tick Bites; Ticks; Viremia | 2014 |
Trace amounts of sporadically reappearing HCV RNA can cause infection.
Topics: Animals; Antiviral Agents; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Pan troglodytes; Phylogeny; Plasma; Ribavirin; RNA, Viral; T-Lymphocytes; Time Factors; Transfusion Reaction; Viremia | 2014 |
Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.
Topics: Antiviral Agents; Coronavirus Infections; Drug Combinations; Drug Therapy, Combination; Greece; Humans; Lopinavir; Male; Middle East Respiratory Syndrome Coronavirus; Phylogeny; Respiratory Tract Infections; Ribavirin; Ritonavir; Viremia; Virus Shedding | 2014 |
Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Tissue Donors; Viral Load; Viremia | 2014 |
[Severe bone marrow aplasia due to triple therapy for hepatitis C virus infection: Apropos of a case].
Topics: Anemia, Aplastic; Anti-Bacterial Agents; Antiviral Agents; Blood Component Transfusion; Drug Therapy, Combination; Filgrastim; Folic Acid; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prednisone; Ribavirin; Viremia; Vitamin B 12 | 2015 |
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Topics: Antiviral Agents; Clinical Decision-Making; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Spain; Treatment Outcome; Viral Load; Viremia | 2015 |
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Valine; Viral Load; Viremia | 2015 |
Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2016 |
Genetic predictors of the response to the treatment of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Female; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viremia | 2015 |
The Attenuation Phenotype of a Ribavirin-Resistant Porcine Reproductive and Respiratory Syndrome Virus Is Maintained during Sequential Passages in Pigs.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Cell Line; Drug Resistance, Viral; Genome, Viral; Immunoglobulin G; Microbial Sensitivity Tests; Mutation; Mutation Rate; Open Reading Frames; Phenotype; Porcine Reproductive and Respiratory Syndrome; Porcine respiratory and reproductive syndrome virus; Ribavirin; Swine; Viral Load; Viremia; Virulence; Virus Replication | 2016 |
The Role of IL28B Genotype in HCV-RNA Baseline Levels.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Retrospective Studies; Ribavirin; RNA, Viral; Viremia | 2016 |
[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2008 |
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Viremia | 2009 |
Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions.
Topics: Adult; Antigens, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-12; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2009 |
[Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viremia | 2009 |
[Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia; Young Adult | 2009 |
[Spontaneous and treatment-induced virological dynamic in the plasma, PBMC and liver tissue in a patient with chronic HBV and HCV coinfection].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B, Chronic; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia | 2009 |
Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors; Viral Load; Viremia | 2009 |
Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Blood; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Metabolic Networks and Pathways; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2010 |
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
Topics: Antiviral Agents; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load; Viremia | 2010 |
Hepatitis C treatment response kinetics and impact of baseline predictors.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2011 |
Poor outcome of adenovirus infections in adult hematopoietic stem cell transplant patients with sustained adenovirus viremia.
Topics: Adenoviridae Infections; Adult; Antiviral Agents; Asymptomatic Infections; Child; Child, Preschool; Cidofovir; Cohort Studies; Cytosine; DNA, Viral; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Viremia; Young Adult | 2010 |
Study of nitric oxide in patients with chronic hepatitis C genotype 4: relationship to viremia and response to antiviral therapy.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitric Oxide; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load; Viremia | 2010 |
[24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia].
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia | 2010 |
Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferons; Male; Medication Adherence; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Viremia | 2010 |
Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.
Topics: Administration, Oral; Animals; Antiviral Agents; Cell Line; Dengue; Dengue Virus; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Inhibitory Concentration 50; Mice; Ribavirin; Viremia | 2011 |
Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy.
Topics: Antiviral Agents; Drug Monitoring; Hepatitis C, Chronic; Humans; Interferons; Molecular Diagnostic Techniques; Predictive Value of Tests; Prognosis; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viremia; Virology | 2011 |
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; CD56 Antigen; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Leukocyte Immunoglobulin-like Receptor B1; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; Natural Cytotoxicity Triggering Receptor 3; Polyethylene Glycols; Receptors, IgG; Receptors, Immunologic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia | 2011 |
[Gene expression profiling in the first twelve weeks of treatment in chronic hepatitis C patients].
Topics: Adult; Alcohol Drinking; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors; Viremia | 2011 |
Gaps in the achievement of effectiveness of HCV treatment in national VA practice.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; United States; United States Department of Veterans Affairs; Viremia | 2012 |
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Viral Load; Viremia | 2011 |
Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2011 |
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.
Topics: Amino Acid Sequence; Antigens, CD; APOBEC-3G Deaminase; CD4-Positive T-Lymphocytes; Cytidine Deaminase; Cytosine Deaminase; Evolution, Molecular; GPI-Linked Proteins; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Interferon-alpha; Molecular Sequence Data; Mutation; Ribavirin; Viral Regulatory and Accessory Proteins; Viremia | 2012 |
Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre.
Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia; Young Adult | 2012 |
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
Topics: Adult; Aged; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon-alpha; Male; Middle Aged; Ribavirin; Silybin; Silymarin; Treatment Outcome; Viremia | 2012 |
A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Topics: Adult; Anti-Retroviral Agents; Cardiac Output; CD4 Lymphocyte Count; Coinfection; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Interferon-alpha; Liver; Liver Cirrhosis; Lung; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viremia | 2012 |
Correlation between HCV viraemia and splenic volume in chronic HCV infected patients: an Egyptian study.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Cross-Sectional Studies; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organ Size; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Spleen; Statistics, Nonparametric; Ultrasonography; Viral Load; Viremia | 2012 |
C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Female; Genetic Variation; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Promoter Regions, Genetic; Receptors, CCR2; Receptors, CCR5; Receptors, Chemokine; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2002 |
Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Topics: Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Vasculitis; Viremia | 2002 |
Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia | 2003 |
Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2003 |
Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite.
Topics: Antiviral Agents; Bilirubin; Cholestasis; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Viremia | 2003 |
Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
Topics: Antiviral Agents; Branched DNA Signal Amplification Assay; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferons; Reagent Kits, Diagnostic; Reproducibility of Results; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Core Proteins; Viral Load; Viremia | 2003 |
The effect of early treatment in children with chronic hepatitis.
Topics: Antiviral Agents; Child; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia | 2003 |
Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.
Topics: Adult; Antiviral Agents; Cell Division; Cells, Cultured; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Lymphocyte Count; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Species Specificity; T-Lymphocytes, Cytotoxic; Viremia | 2003 |
Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Division; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells; Viremia | 2004 |
Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
Topics: Animals; Antiviral Agents; Body Weight; Brain; Cidofovir; Cytosine; Drug Evaluation, Preclinical; Heart; Liver; Lung; Mice; Mice, Inbred BALB C; Organophosphonates; Oxygen; Purines; Respiratory Tract Infections; Ribavirin; Salivary Glands; Spleen; Treatment Outcome; Vaccinia; Vaccinia virus; Viral Plaque Assay; Viremia | 2004 |
Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Viremia | 2004 |
The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viremia | 2004 |
[Therapy with interferon plus ribavirin in hemodialysis patient with PCR-positive viral hepatitis C].
Topics: Adult; Anemia; Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Polymerase Chain Reaction; Renal Dialysis; Ribavirin; RNA, Viral; Vesico-Ureteral Reflux; Viremia | 2004 |
Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.
Topics: Adult; Aged; Amino Acid Sequence; Antigens, Viral; Antiviral Agents; B-Lymphocytes; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Immunologic Memory; Interferon-alpha; Interferon-gamma; Interleukin-10; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Homology; T-Lymphocytes; Treatment Outcome; Viral Core Proteins; Viremia | 2004 |
The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Circoviridae; Circoviridae Infections; DNA, Viral; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Taiwan; Viremia | 2004 |
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2005 |
Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Luminescent Measurements; Male; Middle Aged; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Core Proteins; Viral Load; Viremia | 2005 |
HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2005 |
Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2005 |
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2005 |
Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viremia | 2005 |
Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Treatment Outcome; Viral Core Proteins; Viral Load; Viremia | 2005 |
[Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Child; Child Welfare; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load; Viremia | 2005 |
Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Severity of Illness Index; Treatment Outcome; Viremia | 2006 |
Treatment of hepatitis C virus infection in thalassemia.
Topics: Adolescent; Adult; Antiviral Agents; Biopsy, Needle; Bone Marrow Transplantation; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Mass Spectrometry; Polyethylene Glycols; Ribavirin; Thalassemia; Transfusion Reaction; Treatment Outcome; Viremia | 2005 |
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viremia | 2006 |
[The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia | 2006 |
Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Transplantation, Homologous; Viral Load; Viremia | 2006 |
Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Cholestasis, Intrahepatic; Fibrosis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viremia | 2007 |
A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs.
Topics: 1-Deoxynojirimycin; Animals; Antiviral Agents; Dengue; Disease Models, Animal; Dose-Response Relationship, Drug; Indolizines; Mice; Ribavirin; Time Factors; Tubercidin; Viremia; Virus Replication | 2007 |
Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nucleic Acid Amplification Techniques; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Transcription, Genetic; Viremia | 2007 |
Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera.
Topics: Antibodies, Viral; Combined Modality Therapy; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Outcome and Process Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins; Viremia | 2007 |
Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2007 |
Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2007 |
[Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy, Needle; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2006 |
Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Load; Viremia | 2007 |
Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United Kingdom; Viremia | 2008 |
Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2008 |
Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro.
Topics: Cells, Cultured; Dendritic Cells; Flow Cytometry; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Recombinant Proteins; Ribavirin; Viremia | 2008 |
Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
Topics: Adult; Aged; Antiviral Agents; CD56 Antigen; Female; Flow Cytometry; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphocyte Subsets; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia | 2008 |
Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys.
Topics: Animals; Antibodies, Viral; Combined Modality Therapy; Immunization, Passive; Lassa Fever; Lassa virus; Macaca fascicularis; Male; Ribavirin; Ribonucleosides; Time Factors; Viremia | 1984 |
Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.
Topics: Antiviral Agents; Drug Tolerance; Female; Glomerulonephritis; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nephrotic Syndrome; Recurrence; Ribavirin; Viremia | 1998 |
Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: comparison with interferon alpha alone.
Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Flaviviridae; Hepatitis C, Chronic; Hepatitis, Viral, Human; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 1998 |
Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment.
Topics: Adult; Antiviral Agents; Drug Monitoring; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viremia | 2000 |
Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viremia | 2001 |
Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viremia | 2001 |
Monitoring of clinical and laboratory data in two cases of imported Lassa fever.
Topics: Adult; Africa; Antibodies, Viral; Antiviral Agents; Cytokines; Fatal Outcome; Female; Humans; Lassa Fever; Lassa virus; Male; Middle Aged; Ribavirin; RNA, Viral; Travel; Viral Load; Viremia | 2002 |
Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia | 2002 |
[Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C].
Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Viremia | 2001 |
Needlestick transmission of hepatitis C.
Topics: Accidents, Occupational; Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Asthenia; Exanthema; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Internship and Residency; Lamivudine; Needlestick Injuries; Nelfinavir; Occupational Exposure; Physicians; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia; Zidovudine | 2002 |
Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients.
Topics: Adult; Antiviral Agents; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Viremia | 2001 |
Lack of suppression by ribavirin of HIV viraemia.
Topics: Adult; Hepatitis B virus; HIV-1; Humans; Male; Middle Aged; Ribavirin; Viremia; Virus Replication | 1992 |
Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys.
Topics: Animals; Dengue; Macaca mulatta; Radioimmunoassay; Ribavirin; Ribonucleosides; Viremia | 1990 |
Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.
Topics: Anemia; Female; Hematocrit; Hemoglobins; Hemorrhagic Fever, American; Humans; Interferons; Male; Prospective Studies; Ribavirin; Ribonucleosides; Viremia | 1987 |
Effect of ribavirin and immune serum on Junin virus-infected primates.
Topics: Animals; Antiviral Agents; Arenaviruses, New World; Callithrix; Cell Line; Chlorocebus aethiops; Combined Modality Therapy; Drug Evaluation, Preclinical; Hemorrhagic Fever, American; Immunization, Passive; Kidney; Ribavirin; Ribonucleosides; Viremia; Virus Replication | 1986 |
Lassa fever--new issues raised by field studies in West Africa.
Topics: Africa, Western; Genes, Viral; Humans; Lassa Fever; Lassa virus; Prognosis; Ribavirin; Sierra Leone; Viremia; Virulence | 1987 |
Lassa fever. Effective therapy with ribavirin.
Topics: Administration, Oral; Adult; Antibodies, Viral; Aspartate Aminotransferases; Drug Evaluation; Humans; Immunization, Passive; Injections, Intravenous; Lassa Fever; Lassa virus; Random Allocation; Ribavirin; Ribonucleosides; Time Factors; Viremia | 1986 |